Imatinib (STI571) Resistance in Chronic Myelogenous Leukemia: Molecular Basis of the Underlying Mechanisms and Potential Strategies for Treatment

Publisher： Bentham Science Publishers

E-ISSN： 1875-5607|4|3|285-299

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.4, Iss.3, 2004-03, pp. : 285-299

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New Agents in the Treatment of Chronic Myelogenous Leukemia

By Pinilla-Ibarz Javier   Quintás-Cardama Alfonso  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 7, Iss. 9, 2009-10 ,pp. : 1028-1037

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Treatment of chronic myeloid leukemia when imatinib fails

By Hehlmann Rüdiger   Jung-Munkwitz Susanne   Saußele Susanne  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 2, 2011-02 ,pp. : 269-283

Informa Healthcare

Access to resources Recommend Favorite

Multifaceted Mechanisms for Cell Survival and Drug Targeting in Chronic Myelogenous Leukemia

By  

Current Cancer Drug Targets, Vol. 13, Iss. 1, 2013-01 ,pp. : 69-79

Bentham Science Publishers

Access to resources Recommend Favorite

Chronic Myelogenous Leukemia Guidelines

By  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 5, Iss. 5, 2007-05 ,pp. : 474-474

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Bypass Mechanisms of Resistance to Tyrosine Kinase Inhibition in Chronic Myelogenous Leukaemia

By  

Current Drug Discovery Technologies, Vol. 11, Iss. 2, 2014-06 ,pp. : 145-153

Bentham Science Publishers

Access to resources Recommend Favorite